Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALN-RSV01 in RSV infected lung transplant patients
NCT00658086Phase 2Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Apr 2008
- Primary completion
- Apr 2009
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 2
01
Overview
A Phase 2 trial of asvasiran in respiratory syncytial virus infection (RSV), sponsored by Alnylam Pharmaceuticals. Started Apr 2008; status: completed.
02
Drugs
asvasiran
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT00658086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00658086.